Ambulatory Oxygen Therapy for Individuals With Mild-to-moderate Interstitial Lung Disease

Launched by UNIVERSITY OF ALBERTA · Sep 20, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether portable oxygen therapy can help people with mild-to-moderate interstitial lung disease (ILD) feel better during physical activities. The therapy will be provided for 8 weeks to see if it improves quality of life, helps them exercise more comfortably, reduces shortness of breath, and benefits blood vessel function. The researchers will also explore if regular phone check-ins with a respiratory therapist and extra educational materials make the oxygen therapy more effective.

To be eligible for this study, participants should be between the ages of 65 and 74, have fibrotic ILD, and normally have good oxygen levels at rest but experience lower oxygen levels (80-89%) when active. However, individuals who have used home oxygen therapy in the past year, have certain other health conditions, or significant injuries that affect movement cannot participate. If you or someone you know meets these criteria, this study might be a great opportunity to explore new ways to manage symptoms of ILD.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Individuals with fibrotic ILD (all sub-groups of ILD) who have normal oxygen saturation at rest (SpO2 \> 90%) but develop exertional hypoxemia as demonstrated by a SpO2 = 80-89% with activity (measured during 6MWT).
• Exclusion Criteria:
• • Use of home oxygen therapy within the previous year for the management of ILD, co-morbid conditions that may require oxygen therapy (such as COPD, cardiovascular disease, or other illnesses), or individuals that require the use of non-invasive ventilation. Additionally, individuals with significant cardiovascular, metabolic, neuromuscular or any other disease that could contribute to dyspnea or abnormal cardiopulmonary responses to exercise will be excluded. Individuals with musculoskeletal injuries that prevent them from completing cycle ergometry exercise trials and ambulation will also be excluded. Individuals with peripheral vascular disease will be excluded from measurement of vascular function (flow mediated dilation).